Press releaseGlobe Newswire
Adial Pharmaceuticals
ADIL · NASDAQ
$3.82+$0.20 (+5.52%)TodayMarket closed ·
Prev close $3.62
Latest news
- Press releaseGlobe Newswire
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Press releaseGlobe Newswire
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseGlobe Newswire
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releaseGlobe Newswire
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
- Press releaseGlobe Newswire
Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
- Press releaseGlobe Newswire
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
- NewsVandana Singh
EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug
- NewsVandana Singh
Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsVandana Singh
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Nasdaq Dips 200 Points; Alphabet Posts Upbeat Earnings
- NewsAvi Kapoor
Nasdaq Dips Over 400 Points; Eli Lilly Shares Surge Following Upbeat Earnings
- NewsAvi Kapoor
Dow Jumps Over 200 Points; Uber Shares Fall After Q4 Results
- NewsAvi Kapoor
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- NewsAvi Kapoor
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsVandana Singh
EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- NewsAvi Kapoor
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
- NewsAvi Kapoor
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- NewsAvi Kapoor
Crude Oil Down 2%; GE Aerospace Earnings Top Views
- NewsAvi Kapoor
US Stocks Edge Higher; General Motors Posts Upbeat Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.